Abstract: A method for inhibiting in a mammal the accelerated growth of a solid primary or metastatic tumor resulting from tissue trauma caused surgically, non-surgically, or by tissue ulceration, which method comprises the step of administering to the mammal a therapeutically effective amount of somatostatin or a somatostatin agonist.

Abstract: Biologically active peptides are disclosed of the formula: A.sup.1 --A.sup.2 --A.sup.3 --A.sup.4 --Phe--Arg--TrP--A.sup.5, or a pharmaceutically acceptable salt thereof; A.sup.1 is H or acetyl; A.sup.2 is Ala, or D--Ala; A.sup.3 is Glu or Gln; and A.sup.4 is His or Tyr; A.sup.5 is NH.sub.2, Gly--NH.sub.2, or D--Ala--NH.sub.2. Pharmaceutical compositions containing these peptides are capable of promoting nerve regeneration and increasing muscle mass or preventing muscle atrophy following an injury.

Abstract: A linear peptide which is an analog of naturally occurring, biologically active substance P having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell. The analog has a non-peptide bond instead of a peptide bond between an amino acid residue of the active site and an adjacent amino acid residue, or a synthetic, a .beta.-amino acid, or a .alpha.-amino acid residue replacing two amino acid residues of the active site.

Abstract: A method of treating cancer in a human patient, the method involving administering to the patient a cancer cell inhibiting amount of an analog of a naturally occurring biologically active peptide or a fragment thereof, the peptide being one of mammalian gastrin-releasing peptide, neuromedin B, neuromedin C, amphibian bombesin, or litorin.

Abstract: A bradykinin analog which contains nine or ten amino acid residues and at least one [CH.sub.2 NH] pseudopeptide bond, the analog being useful as an antagonist or agonist of the naturally occuring bradykinin.

Abstract: A device for monitoring the gait of a horse comprises a device (4) for measuring displacement parameters of the horse (2) along at least one axis (Z), processing device (5, 8) for processing the signals coming from the measuring device (4), microprocessor for comparing the amplitude of the output signals from the processing device means with at least one given value characterizing a gait error of the horse (2), and a device (10) for indicating a gait error.

Abstract: A linear (i.e., non-cyclic) analog of biologically active amphibian bombesin, mammalian gastrin-releasing peptide (GRP), or mammalian growth hormone releasing factor (GRF), having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell. Cleavage of a peptide bond in the active site of naturally occurring bombesin, GRP, or GRF is unnecessary for in vivo biological activity. The analog has one of the following modifications: (a) a deletion of an amino acid residue within the active site and a modification of an amino acid residue outside of the active site, (b) a replacement of two amino acid residues within the active site with a synthetic amino acid, a .beta.-amino acid, or a .gamma.-amino acid residue, or (c) a non-peptide bond instead of a peptide bond between an amino acid residue of the active site and an adjacent amino acid residue.

Abstract: A method for promoting regrowth of damaged nerve tissue in a mammal, the method comprising administering to the mammal a nerve tissue regrowth promoting amount of an LHRH antagonist namely, N-Acetyl -D-Naphthylalanine-D-para-Cl-Phe-D-Phe-Ser-Tyr-D-Arg-Phe-Arg-Pro-D-Ala-NH. sub.2.

Abstract: A decapeptide of the formula: N-AC-A.sup.1 -A.sup.2 -A.sup.3 -Ser-A-.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 -A.sup.8 -A.sup.9, wherein each A.sup.1, A.sup.2, and A.sup.3, independently, is D-.beta.-Nal, D-p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, OH, or C.sub.1-3 alkyl), D-benzothienyl (2)-Ala, or D-benzothienyl (1)-Ala; A.sup.4 is p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, or C.sub.1-3 alkyl), Tyr, Lys, Arg, Leu, Trp, or Nal; A.sup.5 is D-Lys, D-Tyr, D-Arg, D-Phe, D-.beta.-Nal, D-Trp, D-homo-Arg, D-diethyl-homo-Arg, D-p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, or C.sub.1-3 alkyl), or D-Lys-.epsilon.-NH-R (where R is H, a branched or straight chain C.sub.1 -C.sub.10 alkyl group, or an aryl group); A.sub.6 is Leu, .beta.-Nal, p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, OH, C.sub.2 F.sub.5, C.sub.1-3 alkyl), or Trp; A.sup.7 is Arg, Lys, or Lys .epsilon.-NH-R (where R is H, a branched or straight chain C.sub.1 -C.sub.6 alkyl group, or an aryl group); A.sub.8 is Pro; and A.sup.

Abstract: A method of treating a mammal suffering from cancer by administering to the mammal somatostatin or an analog thereof, the analog being a hexapeptide analog or higher, in a dosage of at least 25 .mu.g/kg/day.

Abstract: A decapeptide of the formula:N-Ac-A.sup.1 -A.sup.2 -A.sup.3 -SER.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 -A.sup.8 -A.sup.9 -A.sup.10,wherein each A.sup.1, A.sup.2, and A.sup.3, independently, is D-.beta.-Nal, D-p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, OH, or C.sub.1-3 alkyl); A.sup.5 is p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, OH, or C.sub.1-3 alkyl); A.sup.6 is D-Lys, D-Arg, .beta.-Nal, D-.beta.-Nal, D-Trp, D-p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, or C.sub.1-3 alkyl) or D-lys-.epsilon.-NH-R (where R is H, a branched or straight chain or cyclo C.sub.1 -C.sub.10 alkyl group, or an aryl group); A.sup.7 is p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, OH, C.sub.2 F.sub.5, or C.sub.1-3 alkyl), cyclohexyala, or Trp; A.sup.8 is Arg, Lys, or Lys-.epsilon.-NH-R (where R is H, a branched or straight chain or cyclo C.sub.1 -C.sub.10 alkyl group, or an aryl croup); A.sup.9 is Pro; and A.sup.10 is D-Ala-NH.sub.2, Gly-NH.sub.2, D-Ser, or D-Ser-NH.sub.2 ; provided that at least one of A.

Abstract: A flooring unit for an animal enclosure such as a chicken coop or pen is disclosed. The unit is of relatively thin and flat rectangular shape overall and was a planar tread surface, two transverse elongate mounting members at respectively opposite ends and two longitudinal engagement members at respectively opposite sides of the unit moulding. A grid-like area is provided between the members and includes openings through which waste material can pass. The mounting members are designed to receive fastening elements such as screws for securing the unit to an underlying support. Also, they may be of L-shape in cross-section and are complementary to one another so that two similar floor units may be positioned end-to-end with respective, complementary mounting members fitted together. Fastening elements can then be driven through both mounting members and into the support. The engagement members are designed to engage a respective, corresponding engagement member of an adjacent moulding.

Abstract: A therapeutic agent delivery system that includes a biodegradable polymer and a therapeutic agent, the delivery system being coated with a barrier substance that decreases the quantity of the agent released from the system, compared to the quantity of the agent released from a system not coated with the substance, in the forty-eight hours subsequent to the parenteral injection or implantation of the system into a living person or animal.

Abstract: A decapeptide of the formula:N-Ac-A.sup.1 -A.sup.2 -A.sup.3 -Ser-A.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 -A.sup.8 -A.sup.9, wherein each A.sup.1, A.sup.2, and A.sup.3, independently, is D-.beta.-Nal, D-p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, OH, or C.sub.1-3 alkyl), D-Trp, D-benzothienyl (2)-Ala, or D-benzothienyl (1)-Ala; A.sup.4 is p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, or C.sub.1-3 alkyl), Tyr, Lys, Arg, Leu, Trp, or Nal; A.sup.5 is D-Lys, D-Tyr, D-Arg, D-Phe, D-.beta.-Nal, D-Trp, D-homo-Arg, D-diethyl-homo-Arg, D-p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, or C.sub.1-3 alkyl), or D-Lys-.epsilon.-NH-R (where R is H, a branched or straight chain C.sub.1 -C.sub.10 alkyl group, or an aryl group); A.sub.6 is Leu, .beta.-Nal, p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, OH, C.sub.2 F.sub.5, C.sub.1-3 alkyl), or Trp; A.sup.7 is Arg, Lys, or Lys .epsilon.-NH-R (where R is H, a branched or straight chain C.sub.1 -C.sub.6 alkyl group, or an aryl group); A.sub.8 is Pro; and A.sup.

Abstract: A sabot arrangement is produced in accordance with an improved manufacturing method. The sabot arrangement includes a rotational symmetrical sabot body having a central axial bore and radial separating grooves or slots. The radial grooves or slots divide the sabot body into a plurality of equal segments. These slots nearly sever the sabot body into separate segments, so that a material bridge remains near a forward edge and a material bridge remains near a rear edge of the sabot body, which material bridges function as fracture zones.

Abstract: A sabot arrangement is produced in accordance with an improved manufacturing method. The sabot arrangement includes a rotational symmetrical sabot body having a central axial bore and radial separating grooves or slots. The radial grooves or slots divide the sabot body into a plurality of equal segments. These slots nearly sever the sabot body into separate segments, so that a material bridge remains near a forward edge and a material bridge remains near a rear edge of the sabot body, which material bridges function as fracture zones.

Abstract: The invention relates to a device for maintaining on a non-horizontal surface an apparatus adapted to move along said surface.Said device consists, according to the invention, of a support (1) adapted to move normally to the surface carrying the apparatus, of a rocking lever (5) having a flexibility held within a certain range to allow it to accommodate changes in curvature, and of at least two suction cups mounted close to the ends of the rocking lever. There is thus afforded a more reliable, less expensive holding effect.

Abstract: A compound having the formula K-His-Trp-Ser-Tyr-M-Q-Arg-Pro-T, wherein K is N-Acetyl-Sarconsine or pGlu; is D-Phe, D-Trp, D-.beta.-Naphthylalanine, or D-4-X-Phe, wherein X is OH, F, Cl, Br, or Me; Q is Leu, Phe, 4-X-Phe, Trp, or .beta.-Naphthylamine (wherein X is OH, F, Cl, Br, or Me), or an N-Me-derivative thereof; and T is Gly-NH.sub.2, NHCH.sub.3, NHCH.sub.2 CH.sub.3, or NHCH.sub.2 CH.sub.2 CH.sub.3 ; provided that, when Q is Leu or N-Me-Leu, K cannot be pGlu; or a pharmaceutically acceptable salt thereof.

Abstract: A compound having anti-ulcer activity and having the formula ##STR1## wherein D is H, SH, NH.sub.2, OH, R.sup.4 S where R.sup.4 is a lower alkyl group; E is OH or NH.sub.2 ; J is H or aryl; X is CH or N; Y is CH, N, or CT, wherein T is a halogen; Z is CH or N; A is ##STR2## and replaces a hydrogen of D, X, or E; R.sup.1 is H or CH.sub.3 ; L is CH.sub.2 S; Q is O or CH.sub.2 S; n is 0 or 1; 2 m 4; each R.sup.2 and R.sup.3, independently, is H, lower alkyl, cycloalkyl, or arylalkyl; or R.sup.2 and R.sup.3, together with the nitrogen atom to which they are attached, form a 4, 5, or 6 membered heterocyclic ring containing 0, 1, or 2 oxygen atoms and 1, 2, or 3 nitrogen atoms and being unsubstituted or lower alkyl substituted; or a pharmaceutically acceptable salt thereof.